Biodesix, Inc. (the “Company”), is pleased to announce receipt of a CLIA registration number 06D1090464 which allows the Company to commercially market VeriStrat®, the serum molecular diagnostic test described in the Journal of the National Cancer Institute 2007 99(11):838-846. The Company is making VeriStrat® available to qualified physicians in locations where the product is compliant with State and Federal regulations.
Biodesix is a fully integrated molecular diagnostic company enabling personalized health care using mass spectrometry-based molecular profiling. Working with academic and biopharma collaborators, Biodesix uses its proprietary technology, ProTS® to discover and validate diagnostic tests that improve patient outcomes. Biodesix’ first product, VeriStrat, is commercially available for physicians to help guide their treatment of patients with non-small cell lung cancer. For more information on Biodesix, visit www.Biodesix.com.
This press release contains statements that are hereby identified as “forward-looking statements” for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. Such statements are based on management’s current expectations and involve risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors, including, without limitation, the Company’s inability to further identify, develop and achieve commercial success for products and technologies; the risk that the Company’s financial resources will be insufficient to meet the Company’s business objectives; uncertainties relating to the regulatory approval process and changes in relationships with strategic partners. We disclaim any intent or obligation to update these forward-looking statements.